Clinical Trials Logo

Leukaemia clinical trials

View clinical trials related to Leukaemia.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03594955 Terminated - Leukaemia Clinical Trials

First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome

Start date: October 24, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Primary Objective: - Dose escalation: To determine the maximum tolerated dose (MTD) of SAR440234 administered as a single agent in participants with relapsed or refractory acute myeloid leukemia (R/R AML), high risk myelodysplastic syndrome (HR-MDS), or B-cell acute lymphoblastic leukemia (B-ALL), and determine the recommended phase 2 dose (RP2D) for the subsequent Expansion part. - Expansion part: To assess the activity of single agent SAR440234 at the RP2D in participants with R/R AML or HR-MDS. Secondary Objective: - To characterize the safety profile including cumulative adverse drug reactions. - To evaluate the potential immunogenicity of SAR440234. - To assess any preliminary evidence of hematologic response in the Dose Escalation Part.

NCT ID: NCT02310997 Terminated - Lymphoma Clinical Trials

Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)

MAC UCBT
Start date: July 2011
Phase: Phase 2
Study type: Interventional

This trial is looking at using umbilical cord blood from unrelated donors after high dose chemotherapy. It is for people who have cancer of the bone marrow or lymphatic system including leukaemia and lymphoma, or a blood disorder called myelodysplastic syndrome (MDS). The trial is for babies over 4 weeks old, children, and adults up to the age of 45.